Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Vermillion selects CPC to support clearance of new PAD blood test

Vermillion : 20 May, 2008  (Company News)
Vermillion has selected Colorado Prevention Center (CPC) as its academic research organization of choice for the design of a clinical study to support clearance of Vasclir, the company's peripheral artery disease (PAD) blood test, with the US Food and Drug Administration.
Vasclir is a simple blood test that may help determine an individual's risk of having PAD, a serious condition estimated to affect up to 12 million Americans.

'The selection of CPC to support our PAD clinical programme is an important milestone in our product development and commercialisation efforts,' said Gail S Page, president and chief executive officer of Vermillion. 'We selected CPC because of its extensive experience in designing and executing high-quality, cost-effective clinical studies in the field of cardiovascular disease.'

'We are pleased to partner with Vermillion on their clinical programme for Vasclir,' said William Hiatt, MD, president of the Colorado Prevention Center, and professor of medicine and chief of the section of vascular medicine at the University of Colorado Denver School of Medicine. 'Research indicates that within five years of being diagnosed with PAD, one in four patients will suffer a major adverse event, such as heart attack, stroke, amputation or even death. This statistic exemplifies the need for a new blood test that can provide information to doctors and their patients about the risk that a patient may have PAD. Such a blood test could allow earlier measures to be taken to prevent the serious consequences of the disease.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo